Is Placebo Still Ethical in Trials of Incretin Therapies?

Brendon L. Neuen; John W. Ostrominski; Muthiah Vaduganathan

doi:10.1161/circulationaha.125.077277

Is Placebo Still Ethical in Trials of Incretin Therapies?

B Brendon L. Neuen (George Institute for Global Health, University of New South Wales, Sydney) J John W. Ostrominski (Cardiovascular Division, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA (M.C.H.L., J.W.O., B.L.C., S.D.S., M.V.).) M Muthiah Vaduganathan (Division of Cardiovascular Medicine Brigham and Women’s Hospital, Harvard Medical School, Boston, MA (M.V.).)

View Original

APA MLA Chicago BibTeX RIS

Article Details

Journal Circulation

Volume / Issue Vol. 153, Issue 14

Published April 07, 2026

Pages 1005-1008

DOI 10.1161/circulationaha.125.077277

ISSN 0009-7322

Publisher Lippincott Williams & Wilkins

Journal Info

Circulation

Lippincott Williams & Wilkins

ISSN: 0009-7322 Health Sciences

Authors (3)

B

Brendon L. Neuen

George Institute for Global Health, University of New South Wales, Sydney

J

John W. Ostrominski

Cardiovascular Division, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA (M.C.H.L., J.W.O., B.L.C., S.D.S., M.V.).

M

Muthiah Vaduganathan

Division of Cardiovascular Medicine Brigham and Women’s Hospital, Harvard Medical School, Boston, MA (M.V.).

Is Placebo Still Ethical in Trials of Incretin Therapies?

Article Details

Journal Info

Authors (3)

Related Articles from this Journal

Occupational Radiation Safety in Electrophysiology During Pregnancy: Evaluating Uterine Radiation Doses During Catheter Ablations and Device Implantations

Response by Rogers et al to Letter Regarding, “Deep Learning-Based Continuous QT Monitoring to Identify High-Risk Prolongation Events After Class III Antiarrhythmic Initiation”

Clinical Cardiology at the Crossroads: Perspectives on the Next Era at <i>Circulation</i>

ABHD11-Mediated mtDNA Transcription Restored Mitochondrial Function to Attenuate Cardiomyocyte Ferroptosis After Myocardial Infarction

Letter by Li et al Regarding Article, “Deep Learning-Based Continuous QT Monitoring to Identify High-Risk Prolongation Events After Class III Antiarrhythmic Initiation”